Standout Papers

Diagnostic criteria for multiple sclerosis: 2010 Revisions to ... 2003 2026 2010 2018 7.5k
  1. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria (2011)
    Chris H. Polman, Stephen C. Reingold et al. Annals of Neurology
  2. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” (2005)
    Chris H. Polman, Stephen C. Reingold et al. Annals of Neurology
  3. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis (2006)
    Chris H. Polman, Paul O’Connor et al. New England Journal of Medicine
  4. A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis (2003)
    David H. Miller, Omar Khan et al. New England Journal of Medicine
  5. Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis (2006)
    Ludwig Kappos, Jack P. Antel et al. New England Journal of Medicine
  6. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial (2009)
    Kathleen Hawker, Paul O’Connor et al. Annals of Neurology
  7. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis (2011)
    Paul O’Connor, Jerry S. Wolinsky et al. New England Journal of Medicine
  8. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial (2011)
    Ludwig Kappos, David Li et al. The Lancet
  9. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial (2014)
    Christian Confavreux, Paul O’Connor et al. The Lancet Neurology

Immediate Impact

4 by Nobel laureates 6 from Science/Nature 113 standout
Sub-graph 1 of 10

Citing Papers

A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Gut-licensed IFNγ+ NK cells drive LAMP1+TRAIL+ anti-inflammatory astrocytes
2021 StandoutNature
1 intermediate paper

Works of Paul O’Connor being referenced

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
2011 Standout
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
2003 Standout

Author Peers

Author Last Decade Papers Cites
Paul O’Connor 18965 4762 6632 148 24.1k
Emmanuelle Waubant 14895 2839 5953 221 20.4k
Jerry S. Wolinsky 22921 3949 8479 241 27.9k
Eva Havrdová 18266 5102 6056 376 22.9k
Richard A. Rudick 15635 3332 5405 210 21.2k
Michael Hutchinson 13557 3536 6440 293 21.3k
Magnhild Sandberg‐Wollheim 16133 2643 5617 82 19.9k
Stephen C. Reingold 20930 3142 7123 56 25.4k
George C. Ebers 22503 4067 7369 351 31.2k
Jeffrey A. Cohen 12816 3067 5496 305 22.0k
Henry F. McFarland 15024 4057 4741 260 26.6k

All Works

Loading papers...

Rankless by CCL
2026